可切除III期黑色素瘤新辅助免疫治疗的澳大利亚早期真实世界经验
该回顾性研究纳入8家澳大利亚机构中临床试验外接受新辅助免疫检查点抑制剂的可切除IIIB-D期黑色素瘤患者268例,评估真实世界可行性与结局。中位随访12.1个月,联合治疗较单药12个月EFS更高,单药达MPR后接受辅助ICI者RFS更优,仅ITM患者EFS与仅LN患者相似,cCR后未手术者无复发。
要点
- 联合治疗较单药与更高12个月EFS相关(85.6% vs 75.6%,p<0.05)。
- 单药达MPR后接受辅助ICI者12个月RFS优于省略者(100% vs 80.4%,p<0.05)。
- cCR后未手术者无复发,仅ITM与仅LN患者12个月EFS相似(76.2% vs 81.0%,p=0.13)。
核心结论
- 新辅助ICI在真实世界实践中可行,包括仅ITM疾病患者。
- 单药达MPR后接受辅助ICI较省略者结局更优。
研究设计与样本
- 回顾性研究,纳入8家澳大利亚机构临床试验外接受nICI的可切除IIIB-D期黑色素瘤患者268例。
- 收集基线特征、治疗细节、影像与病理反应、EFS及RFS。
主要发现
- 173例(65%)仅LN转移,65例(24%)仅ITM,30例(11%)两者均有。
- 单药198例(74%),联合70例(26%);227例(85%)手术,41例(15%)未手术(25例cCR后、14例进展、2例毒性)。
- MPR 118例(52%)。
- 中位随访12.1个月,联合较单药12个月EFS更高(85.6% vs 75.6%,p<0.05)。
- 单药达MPR后接受辅助ICI者12个月RFS更高(100% vs 80.4%,p<0.05);联合达MPR后未见此差异。
关键数值与推荐
- 联合治疗12个月EFS 85.6%,单药75.6%(p<0.05)。
- 单药达MPR后接受辅助ICI者12个月RFS 100%,省略者80.4%(p<0.05)。
- 仅ITM与仅LN患者12个月EFS 76.2% vs 81.0%(p=0.13)。
临床怎么用
- 真实世界中可考虑新辅助ICI用于可切除IIIB-D期黑色素瘤,包括仅ITM患者。
- 单药治疗达MPR后宜讨论辅助ICI以改善RFS。
- cCR后非手术管理在严密随访下可行且未见复发。
局限性
- 回顾性设计,中位随访仅12.1个月,为早期经验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant immune checkpoint inhibitor therapy (nICI) improves outcomes in stage III melanoma. Real-world data remain limited, especially in patient subgroups ineligible for trials or undergoing approaches deviating from trial protocols. METHODS: Retrospective review of all patients who received nICI outside clinical trials for resectable stage IIIB-D melanoma across 8 Australian institutions. Baseline characteristics, treatment details, radiological and pathological responses, event-free survival (EFS) and recurrence-free survival (RFS) were examined. RESULTS: From June 2023 to October 2025, 268 patients received nICI; 173 (65%) had lymph node (LN) metastases only, 65 (24%) had in-transit metastases (ITM) only, and 30 (11%) had both. Anti-PD-1 monotherapy (mono) was used in 198 patients (74%); 70 (26%) received anti-PD-1 + anti-CTLA-4 (combo). Surgery was performed in 227 patients (85%), while 41 (15%) did not proceed to surgery: 25 following clinical complete response (cCR), 14 due to progression, and 2 due to toxicity. Major pathological response (MPR) was achieved in 118 patients (52%). At a median follow-up of 12.1 months, combo was associated with higher 12-month EFS than mono (85.6% vs 75.6%, p < 0.05). Patients with MPR to mono who omitted adjuvant ICI had lower 12-month RFS than those who received it (80.4% vs 100%, p < 0.05); this difference was not observed after MPR to combo. ITM-only patients had similar 12-month EFS to LN-only patients (76.2% vs 81.0%, p = 0.13). No patient managed nonoperatively after cCR recurred. CONCLUSION: Neoadjuvant ICI is feasible in real-world practice, including for ITM-only disease. Following MPR to mono, adjuvant ICI confers superior outcomes than omitting it.
引用
- Proulx-Rocray F, Symons R, Wang Y, et al. Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma - The early Australian experience. Eur J Cancer. 2026. PMID: 42269243. doi:10.1016/j.ejca.2026.116865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。